Herb Cross - 02 Jan 2026 Form 4 Insider Report for Jasper Therapeutics, Inc. (JSPR)

Reporting relationship: Chief Financial Officer
Issuer ticker: JSPR
Reported as of: 02 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jan 2026, 19:30:17 UTC
Prior SEC filing: 06 Jun 2025
Source filing: View source filing
Reporting owner signature: By: /s/ Herb Cross

Key filing fact

Herb Cross filed Form 4 for Jasper Therapeutics, Inc. (JSPR) on 05 Jan 2026.

Key facts

This page summarizes Herb Cross's Form 4 filing for Jasper Therapeutics, Inc. (JSPR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Jan 2026, 19:30.

Change

Previous filing in this sequence was filed on 06 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001230721 Primary reporting owner

CROSS HERB

Relationship: Chief Financial Officer
Address: C/O JASPER THERAPEUTICS, INC., 2200 BRIDGE PKWY, SUITE 102, REDWOOD CITY
Signature: By: /s/ Herb Cross
Signature date: 05 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

JSPR transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +90,000
Change %
Price: $0.000000
Shares after: 90,000
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Voting Common Stock
Underlying amount: 90,000
Exercise price: $1.84
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/4th of the shares subject to the option shall vest on January 2, 2027, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.